We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,156.00
Bid: 12,124.00
Ask: 12,128.00
Change: -14.00 (-0.12%)
Spread: 4.00 (0.033%)
Open: 12,114.00
High: 12,258.00
Low: 12,114.00
Prev. Close: 12,170.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

How UK PM Johnson decided to delay COVID reopening

Tue, 15th Jun 2021 16:59

* Reuters' vaccine tracker: https://tmsnrt.rs/3zr9NFl

By Alistair Smout

LONDON, June 15 (Reuters) - British Prime Minister Boris
Johnson on Monday delayed by a month his plans to lift the last
COVID-19 restrictions in England after modelling showed that
thousands more people might die due unless reopening was pushed
back.

The move was due to the rapid spread of the Delta
coronavirus variant, which is more transmissible, associated
with lower vaccine effectiveness against mild disease and could
cause more hospitalisations in the unvaccinated.

He said the extra time would be used to speed up Britain's
vaccination programme - already one of the world's furthest
advanced - with two thirds of the population expected to have
had two shots by July 19.

Here are the details behind the decision:

WHAT AND WHO ARE THE MODELS AND THE MODELLERS?

Models commissioned by the government showed that without a
delay to the planned June 21 reopening, in some scenarios
hospitalisations could match previous peaks in cases when
ministers feared the health system could be overwhelmed.

Three models, made by the London School of Hygiene and
Tropical Medicine, Imperial College London and the University of
Warwick, fed into the government's pandemic modelling subgroup
SPI-M-O.

All three found that a delay would lower the peak of a new
wave fuelled by the Delta variant. A two-week extension would
have a significant effect, but four weeks would reduce the peak
in hospital admissions by around a third to a half, SPI-M-O
said.

SPI-M-O will make fresh projections before July 19 when the
full reopening is now expected to take place, with Johnson
saying that he does not want to delay reopening again.

WHAT ABOUT THE VACCINES?

Britain has one of the fastest vaccine rollouts in the
world, with over half of adults receiving both doses and more
than three quarters receiving at least one, which has led some
to question why restrictions need to be extended.

The modellers warned that while protection from vaccines was
not perfect, without them, England would be heading back into
lockdown.

Imperial epidemiologist Anne Cori told reporters that
differences in who was eligible, in rates of uptake, and the
fact that vaccine effectiveness was not 100%, all combined to
create the possibility of a large wave of hospitalisations.

VACCINE AND DELTA

One worrying aspect of the Delta variant is evidence that it
reduces protection from vaccines against symptomatic infection,
although experts still hoped it would work against severe
disease.

As Johnson announced the postponement, Public Health England
published data showing shots made by Pfizer and
AstraZeneca offer high protection against
hospitalisation from the variant identified in India of 96% and
92% respectively after two doses.

Asked if that data, released after the models were made,
would have an impact on the projections, Cori said they had used
different efficacy assumptions for their models, and PHE figures
would help to narrow down the range of likely scenarios.

"The optimistic vaccine efficacy or perhaps the central
(scenarios) are definitely more likely than the most pessimistic
set of vaccine efficacies we had looked at," she said.

WHAT ARE THE SOCIAL-ECONOMIC COSTS?

Many lawmakers in Johnson's own party expressed dismay at
the delay, with Steve Baker saying some people "increasingly
believe they are never going to see true freedom again".

Kevin McConway, emeritus professor of applied statistics at
The Open University, said the delay would buy time to learn more
about the Delta variant, and get more shots in arms.

But he said increased risks of opening on June 21 were hard
to quantify, and economic costs were not being modelled with
anywhere near the same rigour.

"I do wonder how the government can make good decisions on
the balance between restrictions on what we can do, if they have
detailed modelling of infections, vaccines, hospitalisations and
deaths (including information on the likely uncertainties), but
no detailed modelling (that I’ve seen) on the economic and
social costs of the restrictions," he said.
(Reporting by Alistair Smout;
Editing by Josephine Mason and Alison Williams)

More News
Today 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for previously untreated adult patients with mantle cell lymphoma.

Read more
Today 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.

Read more
29 Apr 2024 22:52

J&J, Bristol Myers lose challenges to US drug price negotiation program

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties.

Read more
29 Apr 2024 10:02

LONDON BROKER RATINGS: Deutsche Bank likes Frasers; Barclays cuts JD

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
29 Apr 2024 09:13

AstraZeneca makes progress with Truqap and Enhertu cancer treatments

(Alliance News) - AstraZeneca PLC on Monday said its Truqap drug has been recommended for approval in the EU to treat a form of breast cancer, while also noting trial results for its Enhertu offering.

Read more
29 Apr 2024 07:50

LONDON BRIEFING: Hipgnosis Songs Fund backs new Blackstone bid

(Alliance News) - London's FTSE 100 is called to open higher on Monday, with heady gains for US tech stocks on Friday brightening the mood in Europe and Asia at the start of the new week.

Read more
29 Apr 2024 07:24

AstraZeneca makes progress with two breast cancer treatments

(Sharecast News) - AstraZeneca issued favourable updates on two of its breast cancer treatments on Monday - 'Truqap', or capivasertib, and 'Enhertu', or trastuzumab deruxtecan - following encouraging results from respective phase three trials.

Read more
26 Apr 2024 09:33

LONDON BROKER RATINGS: Peel Hunt cuts ConvaTec to 'reduce'

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning:

Read more
25 Apr 2024 16:57

LONDON MARKET CLOSE: FTSE 100 shakes off red-hot US inflation gauge

(Alliance News) - London's FTSE 100 outperformed on Thursday, enjoying a solid rise on largely well-received corporate earnings and a share price jump for miner Anglo American after it received a takeover bid from peer BHP.

Read more
25 Apr 2024 15:14

London close: Stocks finish mixed as US GDP growth slows

(Sharecast News) - London's stock markets finished with a mixed performance on Thursday, as investors digested a slower-than-expected GDP growth reading from the United States, while a slew of well-received earnings underpinned the top-flight index.

Read more
25 Apr 2024 11:50

LONDON MARKET MIDDAY: FTSE 100 hits high on offer for Anglo American

(Alliance News) - The FTSE 100 was outperforming European markets at midday on Thursday, with the index boosted to a record high thanks to takeover talks.

Read more
25 Apr 2024 10:33

AstraZeneca leaps after smashing first-quarter forecasts

Q1 revenue up 19% to $12.68 bln

*

Read more
25 Apr 2024 09:18

TOP NEWS: AstraZeneca upbeat as cancer drugs underpin sales growth

(Alliance News) - AstraZeneca PLC on Thursday hailed the potential of its drugs pipeline as it delivered impressive growth in sales and profit in the first quarter.

Read more
25 Apr 2024 09:12

LONDON MARKET OPEN: Anglo American jumps on takeover bid from BHP

(Alliance News) - Stock prices in London opened mixed on Thursday, as investors cautiously eye data on the health of the US economy.

Read more
25 Apr 2024 08:38

AstraZeneca blows past analysts' estimates for Q1

(Sharecast News) - AstraZeneca posted better-than-expected revenues and profit for the first quarter of 2024 with both the company and analysts highlighting its drug pipeline.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.